AAPL343.17-4.56 (-1.31%) ▼|ABBV288.70+3.10 (+1.08%) ▲|ABT104.34+0.64 (+0.62%) ▲|ACN250.68+1.31 (+0.52%) ▲|ADBE261.87-1.96 (-0.74%) ▼|AMAT382.31+5.07 (+1.34%) ▲|AMD518.10+1.31 (+0.25%) ▲|AMGN449.29+10.03 (+2.28%) ▲|AMT190.50+1.53 (+0.81%) ▲|AMZN250.30+2.30 (+0.93%) ▲|AVGO326.13+4.45 (+1.38%) ▲|AXP317.16+3.94 (+1.26%) ▲|BA187.98-0.37 (-0.19%) ▼|BAC51.24+0.68 (+1.34%) ▲|BKNG154.60-1.23 (-0.79%) ▼|BLK1,133.45+15.20 (+1.36%) ▲|BMY61.69+0.21 (+0.34%) ▲|BNY147.92+3.28 (+2.26%) ▲|BRK-B545.14+2.95 (+0.54%) ▲|C122.56+1.94 (+1.61%) ▲|CAT685.18-0.19 (-0.03%) ▼|CL94.03-0.02 (-0.02%) ▼|CMCSA22.44-0.26 (-1.12%) ▼|COF204.39+3.05 (+1.51%) ▲|COP150.40-0.41 (-0.27%) ▼|COST1,014.90+11.58 (+1.15%) ▲|CRM248.19-0.39 (-0.15%) ▼|CSCO108.72+2.22 (+2.08%) ▲|CVS94.48+1.01 (+1.08%) ▲|CVX232.24-0.97 (-0.42%) ▼|DE631.72-14.43 (-2.23%) ▼|DHR232.83+2.33 (+1.01%) ▲|DIS112.06-0.46 (-0.41%) ▼|DUK125.19+0.21 (+0.17%) ▲|EMR162.17+0.58 (+0.36%) ▲|FDX303.68+4.96 (+1.66%) ▲|GD355.16+5.80 (+1.66%) ▲|GE288.64+3.00 (+1.05%) ▲|GEV830.21+15.21 (+1.87%) ▲|GILD159.23+3.19 (+2.04%) ▲|GM76.75+0.83 (+1.09%) ▲|GOOG317.09-0.19 (-0.06%) ▼|GOOGL320.15-0.06 (-0.02%) ▼|GS893.84+18.16 (+2.07%) ▲|HD321.62+1.79 (+0.56%) ▲|HON220.34-0.81 (-0.36%) ▼|IBM255.54+1.98 (+0.78%) ▲|INTC87.42+0.46 (+0.53%) ▲|INTU342.94-0.45 (-0.13%) ▼|ISRG458.00+5.71 (+1.26%) ▲|JNJ270.14+6.33 (+2.40%) ▲|JPM336.17+4.59 (+1.38%) ▲|KO92.20-0.51 (-0.55%) ▼|LIN510.11+1.28 (+0.25%) ▲|LLY1,284.44+10.98 (+0.86%) ▲|LMT621.74+17.56 (+2.91%) ▲|LOW200.44+1.76 (+0.88%) ▲|LRCX236.13+6.03 (+2.62%) ▲|MA618.17-5.43 (-0.87%) ▼|MCD252.42+3.96 (+1.59%) ▲|MDLZ63.23-0.58 (-0.90%) ▼|MDT95.57+0.16 (+0.17%) ▲|META636.28-6.34 (-0.99%) ▼|MMM174.40+0.94 (+0.54%) ▲|MO73.81-0.50 (-0.67%) ▼|MRK144.38-0.89 (-0.61%) ▼|MS184.10+4.61 (+2.57%) ▲|MSFT526.66+2.15 (+0.41%) ▲|MU888.06+10.51 (+1.20%) ▲|NEE82.68+0.58 (+0.70%) ▲|NFLX65.29-0.57 (-0.86%) ▼|NKE38.28+0.98 (+2.61%) ▲|NOW157.54-1.42 (-0.89%) ▼|NVDA214.72+3.76 (+1.78%) ▲|ORCL126.40+0.24 (+0.19%) ▲|PEP137.09+1.32 (+0.97%) ▲|PFE30.12+0.09 (+0.28%) ▲|PG160.93-0.09 (-0.06%) ▼|PLTR195.94-0.82 (-0.41%) ▼|PM202.91+3.44 (+1.72%) ▲|QCOM176.91+1.00 (+0.57%) ▲|RTX194.88+3.87 (+2.03%) ▲|SBUX103.05+2.25 (+2.23%) ▲|SCHW90.79+0.21 (+0.23%) ▲|SO92.81-0.08 (-0.09%) ▼|SPG213.24+1.61 (+0.76%) ▲|T21.06+0.13 (+0.60%) ▲|TMO681.35+7.53 (+1.12%) ▲|TMUS144.85-1.69 (-1.15%) ▼|TSLA393.83+21.61 (+5.80%) ▲|TXN285.58+0.89 (+0.31%) ▲|UBER66.80+0.10 (+0.15%) ▲|UNH419.82+1.73 (+0.41%) ▲|UNP294.92+2.05 (+0.70%) ▲|UPS101.05-0.01 (-0.01%) ▼|USB60.20+0.62 (+1.04%) ▲|V405.73-2.19 (-0.54%) ▼|VZ43.53-1.14 (-2.54%) ▼|WFC83.75+1.36 (+1.64%) ▲|WMT121.48+1.59 (+1.33%) ▲|XOM182.82-0.39 (-0.21%) ▼|AAPL343.17-4.56 (-1.31%) ▼|ABBV288.70+3.10 (+1.08%) ▲|ABT104.34+0.64 (+0.62%) ▲|ACN250.68+1.31 (+0.52%) ▲|ADBE261.87-1.96 (-0.74%) ▼|AMAT382.31+5.07 (+1.34%) ▲|AMD518.10+1.31 (+0.25%) ▲|AMGN449.29+10.03 (+2.28%) ▲|AMT190.50+1.53 (+0.81%) ▲|AMZN250.30+2.30 (+0.93%) ▲|AVGO326.13+4.45 (+1.38%) ▲|AXP317.16+3.94 (+1.26%) ▲|BA187.98-0.37 (-0.19%) ▼|BAC51.24+0.68 (+1.34%) ▲|BKNG154.60-1.23 (-0.79%) ▼|BLK1,133.45+15.20 (+1.36%) ▲|BMY61.69+0.21 (+0.34%) ▲|BNY147.92+3.28 (+2.26%) ▲|BRK-B545.14+2.95 (+0.54%) ▲|C122.56+1.94 (+1.61%) ▲|CAT685.18-0.19 (-0.03%) ▼|CL94.03-0.02 (-0.02%) ▼|CMCSA22.44-0.26 (-1.12%) ▼|COF204.39+3.05 (+1.51%) ▲|COP150.40-0.41 (-0.27%) ▼|COST1,014.90+11.58 (+1.15%) ▲|CRM248.19-0.39 (-0.15%) ▼|CSCO108.72+2.22 (+2.08%) ▲|CVS94.48+1.01 (+1.08%) ▲|CVX232.24-0.97 (-0.42%) ▼|DE631.72-14.43 (-2.23%) ▼|DHR232.83+2.33 (+1.01%) ▲|DIS112.06-0.46 (-0.41%) ▼|DUK125.19+0.21 (+0.17%) ▲|EMR162.17+0.58 (+0.36%) ▲|FDX303.68+4.96 (+1.66%) ▲|GD355.16+5.80 (+1.66%) ▲|GE288.64+3.00 (+1.05%) ▲|GEV830.21+15.21 (+1.87%) ▲|GILD159.23+3.19 (+2.04%) ▲|GM76.75+0.83 (+1.09%) ▲|GOOG317.09-0.19 (-0.06%) ▼|GOOGL320.15-0.06 (-0.02%) ▼|GS893.84+18.16 (+2.07%) ▲|HD321.62+1.79 (+0.56%) ▲|HON220.34-0.81 (-0.36%) ▼|IBM255.54+1.98 (+0.78%) ▲|INTC87.42+0.46 (+0.53%) ▲|INTU342.94-0.45 (-0.13%) ▼|ISRG458.00+5.71 (+1.26%) ▲|JNJ270.14+6.33 (+2.40%) ▲|JPM336.17+4.59 (+1.38%) ▲|KO92.20-0.51 (-0.55%) ▼|LIN510.11+1.28 (+0.25%) ▲|LLY1,284.44+10.98 (+0.86%) ▲|LMT621.74+17.56 (+2.91%) ▲|LOW200.44+1.76 (+0.88%) ▲|LRCX236.13+6.03 (+2.62%) ▲|MA618.17-5.43 (-0.87%) ▼|MCD252.42+3.96 (+1.59%) ▲|MDLZ63.23-0.58 (-0.90%) ▼|MDT95.57+0.16 (+0.17%) ▲|META636.28-6.34 (-0.99%) ▼|MMM174.40+0.94 (+0.54%) ▲|MO73.81-0.50 (-0.67%) ▼|MRK144.38-0.89 (-0.61%) ▼|MS184.10+4.61 (+2.57%) ▲|MSFT526.66+2.15 (+0.41%) ▲|MU888.06+10.51 (+1.20%) ▲|NEE82.68+0.58 (+0.70%) ▲|NFLX65.29-0.57 (-0.86%) ▼|NKE38.28+0.98 (+2.61%) ▲|NOW157.54-1.42 (-0.89%) ▼|NVDA214.72+3.76 (+1.78%) ▲|ORCL126.40+0.24 (+0.19%) ▲|PEP137.09+1.32 (+0.97%) ▲|PFE30.12+0.09 (+0.28%) ▲|PG160.93-0.09 (-0.06%) ▼|PLTR195.94-0.82 (-0.41%) ▼|PM202.91+3.44 (+1.72%) ▲|QCOM176.91+1.00 (+0.57%) ▲|RTX194.88+3.87 (+2.03%) ▲|SBUX103.05+2.25 (+2.23%) ▲|SCHW90.79+0.21 (+0.23%) ▲|SO92.81-0.08 (-0.09%) ▼|SPG213.24+1.61 (+0.76%) ▲|T21.06+0.13 (+0.60%) ▲|TMO681.35+7.53 (+1.12%) ▲|TMUS144.85-1.69 (-1.15%) ▼|TSLA393.83+21.61 (+5.80%) ▲|TXN285.58+0.89 (+0.31%) ▲|UBER66.80+0.10 (+0.15%) ▲|UNH419.82+1.73 (+0.41%) ▲|UNP294.92+2.05 (+0.70%) ▲|UPS101.05-0.01 (-0.01%) ▼|USB60.20+0.62 (+1.04%) ▲|V405.73-2.19 (-0.54%) ▼|VZ43.53-1.14 (-2.54%) ▼|WFC83.75+1.36 (+1.64%) ▲|WMT121.48+1.59 (+1.33%) ▲|XOM182.82-0.39 (-0.21%) ▼|
11 C
New York
Monday, October 26, 2026

Tag: TRI TDS

newsFORsourcecompanycontentinformation1releasesmarket

CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity

CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumorsHighlightsThree pillars...

Results of CARsgen’s Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

SHANGHAI, Oct. 25, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that...

2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein

The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant lung adenocarcinoma, further supporting its...

The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England...

PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65; P<0.0001...

2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC

SAN FRANCISCO and SUZHOU, China, Oct. 25, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development,...

Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting

SHAOXING, China, Oct. 25, 2026 /PRNewswire/ -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma")  will publish the phase...

Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing1Building on its leadership in colorectal...

Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026

SHANGHAI, Oct. 23, 2026 /PRNewswire/ -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its...

ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026

SUZHOU, China, Oct. 22, 2026 /PRNewswire/ -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead...

Chen Qiyu: Building on “Affordability & Reliability”, Fosun Expands the Global Reach of Chinese Innovative Drugs

HONG KONG, Oct. 21, 2026 /PRNewswire/ -- On 20 October, the Sustainability Global Leaders Conference 2026 was held in Shanghai. The Conference, themed "Building a...

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

New and updated data across seven assets in lung, colorectal, ovarian, prostate and gastric cancers underscore the potential of AbbVie's oncology portfolio to address diverse...

ACG 2026 Data Show TissueCypher® Identifies Elevated Risk of Progression Beyond Pathology Findings in Barrett’s Esophagus

Studies highlight how molecular risk assessment with TissueCypher can help inform surveillance and treatment decisions beyond biopsy findings aloneFRIENDSWOOD, Texas, Oct. 12, 2026 /PRNewswire/...

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 9, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

Antengene to Present Latest Preclinical Results of ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at ACR 2026

SHANGHAI and HONG KONG, Oct. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited  ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTRI TDS

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers